Clene Inc - Warrants (30/12/2025)
CLNNW - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$22.29K
Close$
$-2.59
144161.1% downside
Current Fair Value
144161.1% downsideOvervalued by 144161.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $22,289.00 |
|---|---|
| Enterprise Value | $12.70 Million |
| Earnings per Share | $-2.65 |
| Beta | 0.79 |
| Outstanding Shares | 12,382,702 |
Return
| Return on Equity | 159.49% |
|---|---|
| Return on Assets | -171.51% |
| Return on Invested Capital | -118.16% |
Valuation & Multiples
| P/E Ratio | -1.08 |
|---|---|
| PEG | -1.33 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 64.44 |
| Enterprise Value to EBIT | -0.59 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.76 |
| Debt to Equity | -0.9 |
Revenue Sources
No data
Last Earnings Call
Report Date
March 17, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Clene Inc
2,021 employees
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally a...